OGB 21501
Alternative Names: OGB-21501Latest Information Update: 15 Jun 2022
Price :
$50 *
At a glance
- Originator Onegene Biotechnology
- Class Antibodies; Hepatoprotectants; Immunoconjugates; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Fibroblast growth factor 21 agonists; Gastric inhibitory polypeptide receptor agonists; Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Fibrosis; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 15 Jun 2022 Early research in Fibrosis in South Korea (Parenteral) (Onegene Biotechnology pipeline, June 2022)
- 07 Dec 2021 Early research in Non-alcoholic steatohepatitis in South Korea (Parenteral) before December 2021 (Onegene Biotechnology pipeline, December 2021)
- 07 Dec 2021 Early research in Obesity in South Korea (Parenteral) before December 2021 (Onegene Biotechnology pipeline, December 2021)